The National Pharmaceutical Pricing Authority (NPPA) has issued a correction to its earlier notification dated December 19, 2024, regarding the price of the Synchrobreathe Inhaler for Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler for M/s Cipla Ltd.
Typographical Error Corrected
A typographical error in the notified price has been identified and corrected in the table within the notification. The price of the Synchrobreathe Inhaler for Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses has therefore been revised.
Corrected Price
The price should have been listed as ₹81.20 per inhaler, not ₹41.20.
The corrected entry in the table is as follows:
| S. No. | Formulation | Unit | Separate Ceiling Price of Synchrobreathe Inhaler in respect of formulations in column (2) (in Rs.) |
|---|---|---|---|
| 2 | Synchrobreathe Inhaler for Budesonide Inhalation (MDI) 200 mcg/dose for 200 doses in one inhaler | 1 inhaler | 81.20 |
Original Order Remains Valid (Except for Correction)
All other notes and content within the original order dated December 19, 2024, remain unchanged and in effect. This correction only applies to the specific price mentioned above. Stakeholders are advised to take note of this correction to ensure accurate pricing and compliance.
